Share

January 08, 2013; 80 (2) Views & Reviews

The thalamus and multiple sclerosis

Modern views on pathologic, imaging, and clinical aspects

Alireza Minagar, Michael H. Barnett, Ralph H.B. Benedict, Daniel Pelletier, Istvan Pirko, Mohamad Ali Sahraian, Elliott Frohman, Robert Zivadinov
First published January 7, 2013, DOI: https://doi.org/10.1212/WNL.0b013e31827b910b
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
3942

Share

Article Information

vol. 80 no. 2 210-219
DOI: 
https://doi.org/10.1212/WNL.0b013e31827b910b
PubMed: 
23296131
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received March 29, 2012
  • Accepted August 6, 2012
  • First Published January 7, 2013.
Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Alireza Minagar, MD,
    2. Michael H. Barnett, MD, PhD,
    3. Ralph H.B. Benedict, PhD,
    4. Daniel Pelletier, MD,
    5. Istvan Pirko, MD,
    6. Mohamad Ali Sahraian, MD,
    7. Elliott Frohman, MD, PhD and
    8. Robert Zivadinov, MD, PhD
  1. Alireza Minagar, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Michael H. Barnett, MD, PhD,
    3. Scientific Advisory Boards:

    1. 1.Bayer, scientific advisory board2.Merck-Serono, scientific advisory board3.Novartis, scientific advisory board4.Sanofi-Aventis, scientific advisory board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. 1.Bayer, speaker honoraria2.Merck-Serono, speaker honoraria3.Novartis, speaker honoraria4.Sanofi-Aventis, speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1. NSW Government (Australia), Paul Brock Fellowship, 2012-2014

    Research Support, Academic Entities:

    1. 1. Multiple Sclerosis Research Australia, principal investigator 2009-2011

    Research Support, Foundations and Societies:

    1. Nerve Research Foundation, The University of Sydney

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Ralph H.B. Benedict, PhD,
    4. Scientific Advisory Boards:

    1. Biogen IdecActelionNovartisBayer

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial Board, Multiple Sclerosis, Neuropsychology, International Journal of MS Care, BMC Neurology

    Patents:

    1. NONE

    Publishing Royalties:

    1. Brief Visuospatial Memory Test, Psychological Assessment Resources

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Shire Inc, Biogen Idec, Accorda

    Research Support, Government Entities:

    1. NIH

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Testified several times in personal injury trials

  4. Daniel Pelletier, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. CNS Imaging Consultant, LLC

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. I have received research grant support from Biogen-Idecover the past two years.

    Research Support, Government Entities:

    1. I receive research grant support from NIH/NINDSR01-NS062885 (PI).

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Istvan Pirko, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Clinical Editor, Nanomedicine:NBM (Elsevier (www.nanomedjournal.com)Associate Editor, BMC Neurology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH, R01NS058698, 2008-current

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Mohamad Ali Sahraian, MD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Elliott Frohman, MD, PhD and
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. TEVA, Biogen Idec, Acorda, Novartis, Bayer for speaking engagements.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. TEVA, Biogen Idec, Acorda, Novartis for speaking engagements. 2009-2011

    Consultancies:

    1. TEVA, Biogen Idec, Acorda, Novartis, Genzyme, Abbott for consulting. 2008-2012

    Speakers' Bureaus:

    1. TEVA, Biogen Idec, Acorda, Novartis. 2008-2012

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Robert Zivadinov, MD, PhD
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Robert Zivadinov received personal compensation from TevaPharmacuticals, Biogen Idec, EMD Serono, Novartis andSanofi-Genzyme for speaking and consultant fees.

    Editorial Boards:

    1. Section Editor for BMC Neurol for demyelinating diseasesfrom 2010.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Teva Pharmacuticals, Biogen Idec, EMD Serono, Novartis andSanofi-Genzyme.

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. The results from the CTEVD study led to the organizationof the IRB approved, (HSIRB #NEU2860310E) unblinded,open-label descriptive study into CCSVI that includespatients with either possible or definite MS. The purposeof this fee-for-service registry study is to enhanceutilization of data on venous anomalies that are obtainedon individuals who have sought information on CCSVI status.

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (A.M.), Louisiana State University Health Sciences Center, Shreveport, LA; Department of Neurology (M.H.B.), Royal Prince Alfred Hospital, Sydney; Brain & Mind Research Institute (M.H.B.), University of Sydney, Australia; The Jacobs Neurological Institute (R.H.B.B., R.Z.) and Buffalo Neuroimaging Analysis Center, Department of Neurology (R.Z.), University at Buffalo, Buffalo, NY; Departments of Neurology and Diagnostic Radiology (D.P.), Yale University, New Haven, CT; Department of Neurology (I.P.), Mayo Clinic, Rochester, MN; Sina MS Research Center (M.A.S.), Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran; and Department of Neurology (E.F.), UT Southwestern Medical Center, Dallas, TX.
  1. Correspondence to Dr. Zivadinov: rzivadinov{at}bnac.net
View Full Text

Article usage

Article usage: December 2012 to May 2023

AbstractFullPdfSource
Dec 2012101Highwire
Jan 2013158081156Highwire
Feb 20132341833Highwire
Mar 20131823631Highwire
Apr 20132263343Highwire
May 20131733528Highwire
Jun 20131502727Highwire
Jul 20131001315Highwire
Aug 20131212527Highwire
Sep 20131052117Highwire
Oct 201312398Highwire
Nov 201397510Highwire
Dec 201347712Highwire
Jan 20147623Highwire
Jan 201413329pmc
Feb 2014581714Highwire
Mar 201483139Highwire
Apr 20145753Highwire
May 201458126Highwire
Jun 20146745Highwire
Jul 201499206Highwire
Aug 20148089Highwire
Sep 2014120118Highwire
Oct 20141111410Highwire
Nov 20146562Highwire
Dec 20145462Highwire
Jan 20157366Highwire
Jan 201504729pmc
Feb 20154999Highwire
Feb 201505628pmc
Mar 2015841311Highwire
Mar 201505931pmc
Apr 20154336Highwire
Apr 201508726pmc
May 20154176Highwire
May 201508138pmc
Jun 20154035Highwire
Jun 201508220pmc
Jul 20153765Highwire
Jul 201508020pmc
Aug 20154422Highwire
Aug 2015010022pmc
Sep 20153421Highwire
Sep 201509521pmc
Oct 20152464Highwire
Oct 201507324pmc
Nov 20155167Highwire
Nov 201509216pmc
Dec 20154810Highwire
Dec 201509622pmc
Jan 20163131Highwire
Jan 201608613pmc
Feb 20164234Highwire
Feb 2016013021pmc
Mar 20164800Highwire
Mar 2016014625pmc
Apr 20163014Highwire
Apr 2016015536pmc
May 20163223Highwire
May 2016010518pmc
Jun 20164312Highwire
Jun 201609120pmc
Jul 20162225Highwire
Jul 2016011620pmc
Aug 20164011Highwire
Aug 2016015317pmc
Sep 20163500Highwire
Sep 2016016314pmc
Oct 20165234Highwire
Oct 2016022617pmc
Nov 20164545Highwire
Nov 2016025320pmc
Dec 201658914Highwire
Dec 2016022415pmc
Jan 20173613Highwire
Jan 2017032216pmc
Feb 20173401Highwire
Feb 2017025617pmc
Mar 20175323Highwire
Mar 2017029019pmc
Apr 20172110Highwire
Apr 20178159271pmc
May 20173645Highwire
May 201725177271pmc
Jun 20172214Highwire
Jun 201720188264pmc
Jul 20173414Highwire
Jul 201713125137pmc
Aug 20172312Highwire
Aug 201715132140pmc
Sep 20171611Highwire
Sep 201713159183pmc
Oct 20174321Highwire
Oct 201718165181pmc
Nov 20173112Highwire
Nov 201728192214pmc
Dec 201746110Highwire
Jan 20185017Highwire
Feb 20182613Highwire
Mar 20184434Highwire
Apr 20187288Highwire
Apr 201814172203pmc
May 201847112Highwire
Jun 20183419Highwire
Jun 201812147161pmc
Jul 20182718Highwire
Aug 201838311Highwire
Aug 201810153180pmc
Sep 20183615Highwire
Oct 20183448Highwire
Nov 201855211Highwire
Dec 201840227Highwire
Jan 201959158Highwire
Feb 201965513Highwire
Mar 201949612Highwire
Apr 201950210Highwire
May 201951210Highwire
Jun 2019641511Highwire
Jul 201945821Highwire
Aug 201938412Highwire
Sep 2019166611Highwire
Oct 201977214Highwire
Nov 20195129Highwire
Dec 20193537Highwire
Jan 20204308Highwire
Feb 202052210Highwire
Mar 20202287Highwire
Apr 202038810Highwire
May 20208843Highwire
Jun 202087518Highwire
Jul 202051014Highwire
Aug 20204315Highwire
Sep 20206558Highwire
Oct 202069121Highwire
Nov 20205212Highwire
Dec 202014417Highwire
Jan 20219762Highwire
Feb 202153105Highwire
Mar 20215837Highwire
Apr 20214642Highwire
May 20217085Highwire
Jun 20216612Highwire
Jul 20215475Highwire
Aug 20214865Highwire
Sep 20215974Highwire
Oct 20216056Highwire
Nov 20216216Highwire
Dec 20214632Highwire
Jan 20224154Highwire
Feb 20227815Highwire
Mar 20225529Highwire
Apr 2022118710Highwire
May 20228986Highwire
Jun 20229936Highwire
Jul 20226699Highwire
Aug 20226924Highwire
Sep 202211987Highwire
Oct 2022942310Highwire
Nov 2022115212Highwire
Dec 20227642Highwire
Jan 202311684Highwire
Feb 202310008Highwire
Mar 202313055Highwire
Apr 202310211Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me

Recommended articles